Diskussion zu CytoSorbents Corporation (Seite 105)

[Aliberto]

Antwort auf Beitrag Nr.: 64.275.304 von xxt am 02.07.20 21:30:18

Ja, war und ist bekannt und genau deswegen werden die Umsatzzahlen für Q2 sehr sehr interessant und die Spannen der Prognosen sind hier ja riesig.

Da gab es ja in den letzten Wochen und Monaten zahlreiche Aussagen seitens des Management zur Produktion ("läuft 24/7 fast auf Vollauslastung" und Backlog Ende März in Höhe von ca. 2.7 Mio Dollar). Siehe unter anderem hier:

http://cytosorbents.mediaroom.com/2020-05-05-CytoSorbents-Re…

"The Company entered April with its first ever sales order backlog of approximately $2.7 million, which orders are expected to be filled in Q2 2020.......... while ramping production 24 hours a day, 7 days a week. Although we are nearing full capacity now, we have the flexibility to rapidly scale production up or down as the global need requires based on whether projected second and third waves of COVID-19 infection materialize. We ended the quarter with orders linked to the rapidly spreading COVID-19 pandemic in many of the countries we serve, and the existing physician user base that has used CytoSorb successfully in their critically-ill and cardiac surgery patients for years. This demand was on top of the already strong results from our existing business, resulting in an exceptional quarter with our first backlog ever."

Heute vorab online eine neue Publikation der Uniklinik Rostock auf PubMed:

https://pubmed.ncbi.nlm.nih.gov/32615564/

Results:
CytoSorb lead to a statistically significant reduction of albumin-bound toxins, total bilirubin and subfractions. Bile acid removal was comparable. MARS demonstrated no removal of cytokines interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-α), whereas CytoSorb allowed for near complete removal. Notably, CytoSorb displayed 50% of lipophilic substance and cytokine removal during the first hour of treatment.

Conclusion:
Compared to MARS, CytoSorb hemoperfusion leads to an initially fast removal of cytokines, TNF-α and IL-6, as well as reduction of albumin-bound toxins such as indirect bilirubin and bile acids in our model. The initial removal is also associated with removal of albumin.

[xxt]

Ist hier diese Video bekannt?

https://youtu.be/qwnv2tSO5I0

Ab Minute 42:40

Ein Mitarbeiter von Cytosorbents berichtet, dass die Nachfrage (seit März 2020?) enorm angestiegen ist und man momentan nicht alle Bestellungen bedienen kann. (So zumindest habe ich es verstanden)

[MarcoPoloX]

Guten Tag an alle CTSO Leser
Da immer wieder geschrieben wird, es könnte eine Übernahme kommen, nimmt es mich wunder, ob es überhaupt betreffend Stimmrechts Aktien etc. dies möglich wäre ? Weiss jemand ob die Aktienstruktur dies zulässt ? Sorry, ich weiss nicht ob es in den USA eine Aktienstruktur gibt, welche eine Übernahme abwehren kann resp. könnte. Viele Grüsse und ein schönes Weekend.

[xxt]

Merkwürdige Preisbildung in Deutschland heute. Nasdaq vorbörslich 10,05 USD, hier 8,40 / 8,65€

[Aliberto]

Aktueller "case of the week" aus Ibbenbühren; Einsatz von CytoSorb bei schwerem ARDS bei Corona-Virus
Infektion:

https://litdb-admin.cytosorb-therapy.com/wp-content/uploads/…

- Insgesamt 14 Behandlungen mit CytoSorb (!)
- Unter kombinierter CRRT+CytoSorb Therapie konnten IL-6 sowie CRP schnell und nachhaltig reduziert und somit die hyperinflammatorische Situation gut unter Kontrolle gebracht werden

Schlussfolgerung

- Bei diesem Patienten resultierte die kombinierte Behandlung aus Standardtherapie, CRRT und CytoSorb-Hämoadsorption in einer deutlichen Kontrolle der hyperinflammatorischen Situation und Verbesserung des klinischen Zustands

- Die CytoSorb-Therapie sollte bei Patienten mit SARS-CoV-2 Infektion möglichst früh begonnen werden, d.h. sobald die Patienten entweder mit schwerem ARDS intubations- und beatmungspflichtig werden, spätestens jedoch bei Indikation zur Anlage einer ECMOTherapie

- PCT ist nach Ansicht des Ärzteteams bei viraler Infektion nicht als Leitparameter nutzbar, IL-6 erscheint hier der beste Indikator für eine protrahierte pro-inflammatorische Immunlage bei COVID-19

[MisterMarket72]

Nachfolgend zwei aktuelle Twitter-Cytosorb-Beiträge. Der erste stammt von einem Arzt aus Mexiko - der Vertrieb scheint also angelaufen zu sein. Der zweite stammt aus Indien.

[xxt]

Ein weiteres Patent für Cytosorbents. Soll damit der Alterungsprozess verlangsamt werden?

http://www.freepatentsonline.com/y2020/0188427.html

[xxt]

https://www.medrxiv.org/content/10.1101/2020.06.28.20133561v…

[MisterMarket72]

Alt aber gut

Wenn mich hier und da doch noch mal Zweifel plagen, zeige ich das nachfolgende Bild irgendwelchen Unbeteiligten und frage sie, ob sie Abbildung c und insbesondere d genauso krass finden wie ich.

Wir einigen uns dann sehr schnell, dass Abbildung b mit Abstand am gesündesten aussieht.

[MisterMarket72]

Antwort auf Beitrag Nr.: 64.220.560 von Aliberto am 29.06.20 14:09:48

Zitat von Aliberto: CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding

http://cytosorbents.mediaroom.com/2020-06-29-CytoSorbents-to…

Hochkarätige CVs dabei:

https://www.baiminstitute.org/index.php/c-michael-gibson/ele…

C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher and educator who pioneered our understanding of the "open artery hypothesis" as well our understanding of the importance of restoring flow downstream in the capillary bed in the "open microvasculature hypothesis" in heart attack. Gibson has been a leading investigator in trials of thrombolytic agents, glycoprotein 2b3a inhibitor agents, thienopyridines, factor Xa inhibitors, lipid lowering agents and new devices. Gibson was named one of the world's most widely published and cited scientists of past decade in 2014 by Thomson Reuters.

Gibson founded and led his own Academic Research Organization (PERFUSE) for 30 years, & has been principal investigator of or led core services for >120 clinical trials, the results of which have been published in leading journals. Under Gibson's direction, PERFUSE created the master database that unified data from over many years of TIMI studies (TIMI 1-50) in nearly 100,000 patients and coordinated data analyses for the TIMI study group and functioned as the TIMI Data Coordinating Center. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban and betrixaban.

Gibson also founded www.wikidoc.org and www.wikipatient.org , widely viewed open source textbooks of medicine. He is Editor-In-Chief of >2,200 active contributors who have edited the content millions of times. Gibson also founded www.clinicaltrialresults.org and has conducted >2,000 TV / video interviews. He has over 340K followers on twitter with millions of impressions at major meetings.

For years, Gibson has been chosen as one of Boston's Top Doctors & U.S. News & World Report also lists Gibson as one of America's top doctors. He has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology and as a Vice Chairman of Medicine.
Disclosures

Dr. Gibson follows the conflict of interest policies set forth by Harvard Medical School and the Beth Israel Deaconess Medical Center. The Baim Institute follows the same conflict of interest policies as Harvard Medical School and Beth Israel Deaconess Medical Center. The dates of payments are based on the date payment was received (on a cash basis) rather than the date of billing (accrual basis).

Executive Position (with $0.00 monies received by Dr. Gibson)

Chief Executive Office, Baim Institute for Clinical Research

Present Research/Grant Funding (within the last year)

Ongoing: Angel Medical Corporation; Bayer Corp.; CSL Behring; Janssen Pharmaceuticals; Johnson & Johnson Corporation; SCAD Alliance;

Terminated but within one year: Portola Pharmaceuticals (contract terminated with BIDMC on 12/31/2017)

Consulting

Amarin Pharama, Amgen, Bayer Corporation, Boehringer Ingelheim, Boston Clinical Research Institute, Cardiovascular Research Foundation, Chiesi, CSL Behring, Eli Lilly, Gilead Sciences, Inc., Impact Bio LTD, Janssen Pharmaceuticals, Johnson & Johnson Corporation, The Medicines Company, MedImmune, Medtelligence, Merck & Co, Inc., The Medicine’s Company, Microport, Novo Nordisk, Pharma Mar, Portola Pharmaceuticals (began 1/1/2018), Sanofi, Somahlution, Verseon Corportation, Web MD

For Trials that Dr. Gibson actively serves as PI of and receives research grant support on an ongoing basis, there is less than $25,000 per year in consulting monies received per the Harvard, BIDMC, Baim policies.

Equity

nference

Royalties as a Contributor

UpToDate in Cardiovascular Medicine

Spouse conflicts of interests (Employee of Boston Clinical Research Institute)

Amarin, Amgen, Bayer, Boehringer Ingelheim, Boston Scientific, Cardiovascular Research Foundation, Chiesi, Eli Lilly, Gilead Sciences, Inc., Impact Bio, Janssen, Johnson and Johnson, The Medicines Company, Medtelligence, MedImmune, Merck & Co. Inc., Novo Nordisk, PharmaMar, Portola, Sanofi, Somahlution, Verseon Corporation

Baim- and Baim-affiliated faculty members disclose the conflicts of interest for the Baim Institute which can be viewed here.